Recent efforts have identified multiple dysregulated signaling pathways in pancreatic cancer development and progression, many of which appear to be reasonable targets including PI3K/mTOR, SIRT1, and ALK [143–146]. The gene discussed is SIRT1; the disease is pancreatic neoplasm.